Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Moderate Buy” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $12.00.

REPL has been the topic of several recent analyst reports. Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Tuesday, June 30th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, August 26th.

Get Replimune Group alerts:

Check Out Our Latest Stock Report on Replimune Group

Insider Activity

In other Replimune Group news, CAO Andrew Schwendenman sold 7,632 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $98,987.04. Following the transaction, the chief accounting officer directly owned 99,425 shares in the company, valued at $1,289,542.25. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the sale, the chief executive officer directly owned 708,151 shares in the company, valued at $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock valued at $1,038,364 in the last ninety days. 5.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of REPL. Essential Partners LLC increased its holdings in Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares in the last quarter. Allworth Financial LP acquired a new position in Replimune Group in the second quarter worth $62,000. Legal & General Group Plc bought a new stake in shares of Replimune Group during the second quarter worth $85,000. WINTON GROUP Ltd bought a new stake in shares of Replimune Group during the second quarter worth $115,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Replimune Group during the second quarter worth $119,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Stock Down 0.7%

NASDAQ REPL opened at $12.87 on Friday. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The stock’s 50 day moving average is $12.66 and its two-hundred day moving average is $8.96. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.09 and a beta of 0.94. Replimune Group has a 1-year low of $1.50 and a 1-year high of $16.33.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Equities analysts forecast that Replimune Group will post -2.81 earnings per share for the current fiscal year.

About Replimune Group

(Get Free Report)

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.

Recommended Stories

• Five stocks we like better than Replimune Group
• Aeluma’s Selloff Could Be Setting Up Its Next Big Move
• Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
• The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
• The Fed’s Rate Hike Could Backfire If Oil Prices Collapse

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.